To further evaluate the effects of selective BCR–ABL and/or JAK2 inhibition therapy on Ph+ALL LPCs in vivo, the recipient mice transplanted with LPCs were randomized to different treatment groups on day 15 post-transplant and were treated with various single or dual drug interventions for 14 days (Fig. 5a). This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.